Immunovant Inc.
IMVT
Immunovant, Inc. ( Immunovant, we or the Company ) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor ( FcRn ), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$509M
▼ -22.2% YoY
Op. Margin
–
ROIC
–
Cash Flow & Balance Sheet
FCF (TTM)
-$395M
▼ -8.1% YoY
Op. Cash Flow (TTM)
-$395M
▼ -8.4% YoY
Net Debt
-$722M
Net Cash Position
Cash & Equiv.
$722M
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with IMVT
Held by ETFs
IMVT is in 51 US ETFs. The largest of them, with IMVT's weight in each:
Immunovant (IMVT) in two numbers
Questions about Immunovant
Does Immunovant (IMVT) pay a dividend?
No. Immunovant (IMVT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 3 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in IMVT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IMVT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.